2C-I

2C-I is a psychedelic phenethylamine of the 2C family. It was first synthesized by Alexander Shulgin and described in his 1991 book PiHKAL: A Chemical Love Story. The drug is used recreationally for its psychedelic and entactogenic effects and is sometimes confused for its more potent chemical cousin 25I-NBOMe, nicknamed 'Smiles,' in the media.Analogues and derivatives of 2C-I: 2C-I is a psychedelic phenethylamine of the 2C family. It was first synthesized by Alexander Shulgin and described in his 1991 book PiHKAL: A Chemical Love Story. The drug is used recreationally for its psychedelic and entactogenic effects and is sometimes confused for its more potent chemical cousin 25I-NBOMe, nicknamed 'Smiles,' in the media. In the early 2000s, 2C-I was sold in Dutch smart shops after the drug 2C-B was banned. According to the US Drug Enforcement Administration, 2C-I is taken orally or snorted in a powder form. In December 2003, the European Council issued a binding order compelling all EU member states to ban 2C-I within three months. As of October 31, 2016, 2C-I is a controlled substance (Schedule III) in Canada. 2C-I is a schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A schedule 9 drug is outlined in the Poisons Act 1964 as 'Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of the CEO'. Sveriges riksdag added 2C-I to schedule I ('substances, plant materials and fungi which normally do not have medical use') as a narcotic on March 16, 2004, published by the Medical Products Agency in their regulation LVFS 2004:3. In the United Kingdom, 2C-I is controlled as a Class A substance. As of July 9, 2012, in the United States 2C-I is a Schedule I substance under the Synthetic Drug Abuse Prevention Act of 2012, making possession, distribution and manufacture illegal. A previous bill, introduced in March 2011, that would have done the same passed the House of Representatives, but was not passed by the Senate.